Literature DB >> 29515224

Blood potassium and urine aldosterone after doxapram therapy for preterm infants.

Tomoyuki Shimokaze1, Katsuaki Toyoshima2, Jun Shibasaki2, Yasufumi Itani2.   

Abstract

OBJECTIVE: We often encounter infants who developed hypokalaemia following low-dose doxapram for apnea of prematurity (AOP). AIMS: To determine changes in blood potassium (K+) levels after doxapram administration. STUDY
DESIGN: We studied infants born before 30 weeks gestation. Doxapram (0.1-0.3 mg/kg/h) in addition to methylxanthines was used to treat AOP refractory to methylxanthines.
RESULTS: Twenty-five infants received doxapram were studied. Fifty-two percent developed hypokalemia (<3.0 mEq/L) during doxapram administration. Time after starting doxapram to nadir blood K+ (<3.0 mEq/L) level was 11 days. Blood K+ levels normalized after 5 days of stopping doxapram administration. Data at 10 days before and after and at the time of doxapram administration were, respectively: lowest blood K+ level: 3.9, 3.0, and 3.6 mEq/L; urine aldosterone: 90, 206, and 146 pg/μg creatinine. Blood pH, blood pressure and urine volume were similar.
CONCLUSIONS: Doxapram-induced hypokalemia may be due to an inappropriate increase in aldosterone levels.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29515224     DOI: 10.1038/s41372-018-0087-x

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  2 in total

1.  Precision Dosing of Doxapram in Preterm Infants Using Continuous Pharmacodynamic Data and Model-Based Pharmacokinetics: An Illustrative Case Series.

Authors:  Jarinda A Poppe; Willem van Weteringen; Lotte L G Sebek; Catherijne A J Knibbe; Irwin K M Reiss; Sinno H P Simons; Robert B Flint
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

2.  The bioavailability and maturing clearance of doxapram in preterm infants.

Authors:  Robert B Flint; Sinno H P Simons; Peter Andriessen; Kian D Liem; Pieter L J Degraeuwe; Irwin K M Reiss; Rob Ter Heine; Aline G J Engbers; Birgit C P Koch; Ronald de Groot; David M Burger; Catherijne A J Knibbe; Swantje Völler
Journal:  Pediatr Res       Date:  2020-07-22       Impact factor: 3.756

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.